On August 7, MEDBOT-B rose 5.09% in regular trading, trading at HKD 23.12/share, with turnover of HKD 91.72 million.

On the news front, the company's surgical robot export volume has surged significantly, with overseas scale effects beginning to materialize. The company previously issued a profit alert forecasting first-half net profit of RMB 28-40 million, compared with a net loss of RMB 115 million a year earlier, marking its first-ever half-year profitability. Revenue grew approximately 200%-230% year-over-year, with the core Toumai laparoscopic surgical robot recording overseas revenue growth exceeding 450%. Global commercial installations surpassed 200 units with orders exceeding 300 units, spanning over 60 countries and regions. Additionally, Da Hua Securities initiated coverage with a Buy rating and HKD 29 target price, citing the company's 5G remote surgery capabilities and global expansion prospects, projecting a 73.8% revenue CAGR from 2025 to 2028.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)